• Lead Drug FGL Found To Prevent Impaired Cognition
• R&D Update, Publication & Conference Presentation
• CHDI selects ENKAM’s compounds for preclinical tes
• Presentation at BIO-Europe
• Attendance at Conferences
• Participation at Conference
• The ENKAM approach shows potential in treatment of
• Discovery of Novel Compound Classes
• Positive Preclinical Data - Traumatic Brain Injury
• Appointment of Executive Chairman
• New Promising Treatment of Alzheimer’s Disease
• EU 6FP Grants EUR9.7 million to European Research
• Glossary

New Promising Treatment of Alzheimer's Disease:

Successful Completion of Phase I Study

_________________________________________________________________

Copenhagen, Denmark, May 18 2005 – Today ENKAM Pharmaceuticals A/S announces the completion of the first phase I clinical study for the synthetic peptide FGL_L, which proved to be well tolerated and safe. In the study, 24 healthy males received FGL_L by intranasal administration at one of the three dose ranges.

Throughout a broad range of models, including one Alzheimer Model, FGL_L showed both neuroprotection and improvement of the memory and learning capability, which gives promise for FGL_L to effectively treat Alzheimer’s disease. Furthermore, FGL_L also demonstrated enhancement of memory and learning capability in normal animals.

“The effect of the molecule is unique by making the nerve cells much more vital and improving their communication. We therefore expect that FGL_L can positively affect the ability of patients to learn and remember,” says cofounder and professor Elisabeth Bock, MD.

Blockbuster potential

Following the successful completion of this study with FGL_L, ENKAM now plans to progress the development of FGL_L into phase II. To accelerate the development of FGL_L through phase II and to the market ENKAM is actively pursuing a partnership.

“If we can achieve the same results in humans that we registered in the pharmacological studies this is a treatment with blockbuster potential,” states Morten Albrechtsen, MD and CEO at ENKAM.

FGL_L – a different and unique approach

FGL_L emerged from ENKAM’s research of the protein NCAM (the Neural Cell Adhesion Molecule). FGL_L is a synthetic peptide able to prevent and contra-act beta-amyloid accumulation, the major hallmark of Alzheimer’s disease. Furthermore, FGL_L seems to prevent brain cells from dying and to restore the functionality of the already affected brain cells.

“FGL_L belongs to a novel class of drugs, namely the NCAM mimetics that selectively target the FGF receptor in the brain. In the preclinical research, FGL_L reduced amyloid load, protected neurons from dying and normalized short and long term memory,” explains the Head of Clinical Development Ravi Anand, MD, who has been working for more than two decades in clinical development, where he has developed several marketed CNS treatments.